These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 12867061)

  • 1. Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.
    Bonomi P
    Lung Cancer; 2003 Aug; 41 Suppl 1():S43-8. PubMed ID: 12867061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of tyrosine kinase inhibitors in lung cancer.
    Ansari J; Palmer DH; Rea DW; Hussain SA
    Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.
    Thomas M
    Cancer Nurs; 2003 Dec; 26(6 Suppl):21S-25S. PubMed ID: 15025409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib (Iressa) trials in non-small cell lung cancer.
    Johnson DH
    Lung Cancer; 2003 Aug; 41 Suppl 1():S23-8. PubMed ID: 12867059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
    Perez-Soler R
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S7-14. PubMed ID: 17239291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of EGFR inhibitors in nonsmall cell lung cancer.
    Ciardiello F; De Vita F; Orditura M; Tortora G
    Curr Opin Oncol; 2004 Mar; 16(2):130-5. PubMed ID: 15075904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.
    Perez-Soler R
    Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S20-3. PubMed ID: 15638953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ZD1839 (Iressa) in non-small cell lung cancer.
    Herbst RS; Kies MS
    Oncologist; 2002; 7 Suppl 4():9-15. PubMed ID: 12202783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
    Grünwald V; Hidalgo M
    J Natl Cancer Inst; 2003 Jun; 95(12):851-67. PubMed ID: 12813169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecules with EGFR-TK inhibitor activity.
    Albanell J; Gascón P
    Curr Drug Targets; 2005 May; 6(3):259-74. PubMed ID: 15857287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor.
    Natale RB
    Clin Lung Cancer; 2003 Sep; 5 Suppl 1():S11-7. PubMed ID: 14641989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of epidermal growth factor inhibitors.
    Toffoli G; De Mattia E; Cecchin E; Biason P; Masier S; Corona G
    Int J Biol Markers; 2007; 22(1 Suppl 4):S24-39. PubMed ID: 17520578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.
    Lau SCM; Batra U; Mok TSK; Loong HH
    Drugs; 2019 Jun; 79(8):823-831. PubMed ID: 31069718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Sequist LV
    Oncologist; 2007 Mar; 12(3):325-30. PubMed ID: 17405897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erlotinib: a new therapeutic approach for non-small cell lung cancer.
    Bonomi P
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1395-401. PubMed ID: 12882624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
    Burotto M; Ali SA; O'Sullivan Coyne G
    Expert Opin Drug Saf; 2015 Jan; 14(1):97-110. PubMed ID: 25345687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
    Pirker R; Minar W; Filipits M
    Clin Lung Cancer; 2008; 9 Suppl 3():S109-15. PubMed ID: 19419924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.